

NCIC CLINICAL TRIALS GROUP  
**BRAIN**  
DISEASE SITE COMMITTEE MEETING AGENDA  
**OPEN SESSIONS**

Venue: Carlyle Room

Date: Saturday, May 2<sup>nd</sup> 2015 Time: 9:00 a.m. – 12:00 p.m.

Chair: Dr. Warren Mason

9:00 am      **Welcome and Introductions**

**Completed Studies**

9:00 am      **CE.5 (EORTC 22033-26033):** Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study - molecular substudy submitted to ASCO 2015      **W. Mason**

9:05 am      **CE.5S:** Impact of chemotherapy (temozolomide) versus radiotherapy treatment on work, social function, anxiety and depression throughout the continuum of care in patients with low grade glioma in Canada      **A. Leis & M. Parkinson**

9:10 am      **IND. 204:** A Phase II study of the Phosphatidylinositol-3-OH Kinase (PI3K) inhibitor PX-866 in recurrent glioblastoma - published in Neuro-Oncology      **M. Pitz**

**Trials Closed to Accrual**

9:15 am      **CE.6:** A Randomized Phase III Study of Temozolomide a Short- Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients      **J. Perry & N. Laperrier**

**Actively Accruing Trials**

9:20 am      **CEC.1 (EORTC 26053\_22054):** Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma. The CATNON Intergroup Trial      **W. Mason & C. O'Callaghan**

9:25 am      **CEC.3 (NCCTG N107C):** A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease      **D. Roberge**

**Trials Pending Activation**

9:30 am      **CEC.5 (ALLIANCE 221208):** Randomized Phase II Study: Corticosteroids + Bevacizumab vs Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases      **C. Chung**

9:45 am **CEC.6 (NCCTG N0577):** Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma

**W. Mason & C. O'Callaghan**

10:00-10:15 Coffee Break

### **New Trials for Discussion**

10: 15 am **IND.222:** A phase I/II trial of AZD2014 with temozolomide in patients with GBM at first progression

**C. Maurice and W.Mason**

10: 30 am A randomized phase II trial of Toca511 with Toca FC for patients with newly diagnosed GBM receiving RT with (MGMT methylated) and without (MGMT unmethylated) Temozolomide

**J. Skillings**

10:55 am Triphase Pipeline for GBM

**M. Trikha**

11:20 am A Phase II Trial of SMO/AKT/FAK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations: ALLIANCE A071401

**W. Mason & C. O'Callaghan**

11:30 am A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation: ALLIANCE A071102

**W. Mason**

### **Miscellaneous**

11:40 am Terry Fox Research Institute (TRFI) Grant: Therapeutic Targeting of GBM Project Status Report

**W. Mason**

11:45 International Rare Cancer Initiative (ICRI) – Medulloblastoma Concept

**W. Mason**

11:50 am Report from NCIC CTG Leadership Retreat

**W. Mason & C. O'Callaghan**

11:55 am Report from IND Committee

**M. Pitz**

12:00 pm **Closing Remarks**